Efimosfermin Biosimilar – Anti-FGF21 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2226; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Efimosfermin Biosimilar is a novel therapeutic protein that has gained significant attention in the field of medical research due to its unique structure, potent activity, and promising applications. This fusion protein is designed to target and modulate the activity of fibroblast growth factor 21 (FGF21), a key regulator of metabolism and energy balance. In this article, we will delve deeper into the structure, activity, and potential applications of Efimosfermin Biosimilar as a research grade therapeutic protein.
Efimosfermin Biosimilar is a fusion protein composed of two distinct components: the Fc region of human immunoglobulin G1 (IgG1) and the extracellular domain of FGF21. The Fc region serves as the backbone of the protein, providing stability and facilitating its binding to FGF21 receptors. On the other hand, the extracellular domain of FGF21 is responsible for the therapeutic activity of Efimosfermin Biosimilar.
The Fc region of IgG1 is a well-characterized protein with a molecular weight of approximately 50 kDa. It consists of two heavy chains and two light chains, connected by disulfide bonds. The Fc region is responsible for the effector functions of IgG1, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). By incorporating the Fc region into Efimosfermin Biosimilar, the protein gains enhanced stability and a longer half-life in the body, making it an ideal candidate for therapeutic use.
The extracellular domain of FGF21 is a 21 kDa protein that plays a crucial role in regulating metabolism and energy balance. It is composed of 181 amino acids and contains a β-trefoil structure, which is essential for its binding to FGF21 receptors. The extracellular domain of FGF21 is responsible for the therapeutic activity of Efimosfermin Biosimilar, making it a potent and specific modulator of FGF21 signaling.
The primary mode of action of Efimosfermin Biosimilar is through its binding to FGF21 receptors. FGF21 receptors are transmembrane proteins that belong to the fibroblast growth factor receptor (FGFR) family. These receptors are expressed in various tissues, including the liver, adipose tissue, and pancreas, and play a crucial role in regulating metabolism and energy balance.
Upon binding to FGF21 receptors, Efimosfermin Biosimilar activates downstream signaling pathways, leading to the modulation of key metabolic processes. These include increasing insulin sensitivity, promoting fat burning, and reducing glucose production in the liver. By targeting FGF21 receptors, Efimosfermin Biosimilar offers a unique approach to treating metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease.
Efimosfermin Biosimilar has shown promising results in preclinical studies, making it a potential candidate for various therapeutic applications. One of the key areas where Efimosfermin Biosimilar could have a significant impact is in the treatment of type 2 diabetes. By improving insulin sensitivity and reducing glucose production, Efimosfermin Biosimilar could help regulate blood sugar levels and improve glycemic control in diabetic patients.
Another potential application of Efimosfermin Biosimilar is in the treatment of obesity. By promoting fat burning and reducing appetite, Efimosfermin Biosimilar could aid in weight loss and improve metabolic health in obese individuals. It could also have a role in treating non-alcoholic fatty liver disease, a condition closely linked to obesity and insulin resistance.
Furthermore, Efimosfermin Biosimilar could also have potential applications in other metabolic disorders, such as dyslipidemia and metabolic syndrome. By modulating
ProteoGenix catalogue number PX-TA2226. For research use only.
Target: Efimosfermin Biosimilar – Anti-FGF21 fusion protein – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
